Clinical Trial Update: Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial is evaluating sacituzumab govitecan in combination with Tagitanlimab for resectable head and neck squamous cell carcinoma, and the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)
• Tagitanlimab

Snippet

Sponsor: West China Hospital | Conditions: Resectable Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING